anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method of delivering epinephrine includes placing a distal end surface of a medical injector into contact with a target location of a patient. The medical injector includes a housing, an energy storage member, and a medicament container containing a dose of epinephrine effective for administration to the patient experiencing anaphylaxis and having a weight of less than 15 kg. The medicament container is coupled to a needle. The medical injector is actuated such that the energy storage member produces a force to move the needle from a first needle position to a second needle position. A distal tip of the needle extends from the distal end surface by a distance of between 7 millimeters and 8 millimeters when the needle is in the second needle position. A portion of the force is exerted to expel the dose of epinephrine when the needle is in the second position.
A composition for treating cancer comprising an intralesional injection solution including at least one poloxamer(RTM) dissolved in a solvent and at least one anti-cancer active pharmaceutical ingredient dissolved in the injection solution. The anti-cancer active pharmaceutical ingredient may comprise a chemotherapeutic agent such as an alkylating agent or antimetabolite agent or an infectious disease virus programmed to infect the cancer. The concentration of the agent may be dependent upon the body surface area of the patient. The poloxamer(RTM) may be poloxamer 407 or poloxamer 188 or both. The poloxamer(RTM) concentration may be from 1% to 50%. The poloxamer(RTM) may be selected to inhibit the normal MDR proteins on the surface of cancer cells which make up the cancer. The poloxamer(RTM) may be a liquid upon injection and a gel following injection. The patient may be a companion animal such as a cat or dog.
<P>PROBLEM TO BE SOLVED: To provide a safe and effective antifungal agent against filamentous fungi, containing a substance produced by a microorganism.  <P>SOLUTION: This antifungal agent against the filamentous fungi is characterized by containing the substance produced by the microorganism belonging to the genus Enterococcus. In particular, the microorganism is preferably Enterococcus faecalis TH-10. An antifungal agent obtained by inoculating and fermenting the microorganism. The antifungal agent is usefully used as a skin- application agent, an agrochemical and a land-improving agent.  <P>COPYRIGHT: (C)2004,JPO
The GEMS-H is a hip-type assist device developed by the Samsung Advanced Institute of Technology. The GEMS-H is worn around the waist and fastened at the waist and thighs by a set of belts with velcro to assist motion at the hip joints. The device weighs 2.1kg, and has 2 brushless direct current motors running on a rechargeable lithium ion battery. The normal operation time for the device is 2 hours. The GEMS-H is available in three sizes to fit various waist/hip sizes: small, medium, and large. The width of each version can be adjusted further to fit individual body size within the circumference range. Also, the thigh frames are available in three sizes (large, medium, and small) for different leg lengths. It is controlled through a custom built application on a hand held tablet.
The effectiveness and safety of estradiol and progesterone capsules, 0.5 mg/100 mg and 1 mg/100 mg, on moderate to severe vasomotor symptoms (hot flushes) due to menopause were examined in a 12-week randomized, double-blind, placebo-controlled substudy of a single 52-week safety study. A total of 726 postmenopausal women were randomized to multiple dose combinations of estradiol and progesterone, and placebo; these women were 40 to 65 years of age (mean 54.6 years) and had at least 50 moderate to severe vasomotor symptoms per week at baseline. The mean number of years since last menstrual period was 5.9 years, with all women undergoing natural menopause. The primary efficacy population consisted of women who self-identified their race as: White (67%), Black/African American (31%), and “Other” (2.1%). In the substudy evaluating effects on moderate to severe vasomotor symptoms, a total of 149 women received estradiol and progesterone capsules, 0.5 mg/100 mg, 141 women received estradiol and progesterone capsules, 1 mg/100 mg, and 135 women received placebo.

The evaluated co-primary efficacy endpoints included: 1) mean weekly reduction in frequency of moderate to severe vasomotor symptoms with estradiol and progesterone capsules compared to placebo at Weeks 4 and 12 and 2) mean weekly reduction in severity of moderate to severe vasomotor symptoms with estradiol and progesterone capsules compared to placebo at Weeks 4 and 12.

Overall, estradiol and progesterone capsules, 0.5 mg/100 mg and 1 mg/100 mg, statistically significantly reduced both the frequency and severity of moderate to severe vasomotor symptoms from baseline compared with placebo at Weeks 4 and 12. The change from baseline in the frequency and severity of vasomotor symptoms observed and the difference from placebo are shown in Table 3 and Table 4, respectively.

Adjusting for potential confounders such as BMI, smoking, alcohol use, and baseline estradiol level, treatment with estradiol and progesterone capsules, 0.5 mg/100 mg or 1 mg/100 mg, did not demonstrate statistically significant reductions in both frequency and severity of moderate to severe vasomotor symptoms by Week 12 in women who self-identified as Black/African Americans (data not shown).
PURPOSE:A cosmetic for eye make-up such as eye shadow, etc., having high safety which a black type pigment does not possess, using fine powder of ferric tannate complex as a colorant. CONSTITUTION:A ferric salt is added to an aqueous solution of tannic acid with stirring. The molar ratio of the ferric salt to tannic acid is 0.5-2.0. After the addition of the ferric salt is over, an aqueous solution of caustic soda is added to the reaction mixture and adjusted to a pH of 7. The neutralized solution is heated with stirring, cooled, filtered by a filter press, etc., washed with warm warer, and filtered hydrous cake of ferric tannate is dries in an oven, to give black ferric tannate. This is pulverized by a ball mill, etc., to give fine powder having particle diameters of 10-0.1mu. The fine powder whose surface is subjected to hydrophobic treatment with a monofatty acid ester of sorbitan, etc. can be also used.
Participants will receive matching placebo (Treatment D) or JNJ- 64140284 (as formulation 1) in Treatment E or JNJ-64140284 (as formulation 2) in Treatment F. Participants will receive treatment in either of 6 treatment sequence (DEF, EFD, FDE, FED, DFE or EDF) in Period 1, 2, or 3 under fed condition. Each period is separated by washout period of 5 days.
Pediatric intensive care nurses care not only for critically ill children but also for their caregivers. Under unfamiliar and critical situations, caregivers demand nursing care to ease their negative emotions and to cope. Pediatric intensive care nurse is the bridge to connect the healthcare team to the caregivers in the pediatric intensive care units (PICU). Previous literature discussed the relationship between nurses and family caregivers as therapeutic and meaningful, which consisted of elements like mutual respect, empathy, support, and more. Nurses' and family caregivers' roles shifted and changed in different times and settings. However, the relationship between the two had not been acknowledged in the PICU context. A review of the literature showed that the interaction between the pediatric intensive care nurse and the family caregivers involved six elements. Consequently, a conceptual framework was developed which may help represent the essence of the nurse-caregiver relationship.

This study aims to explore the lived experience as to the meaning of nurse-caregiver relationship among pediatric intensive care nurses in Hong Kong. Descriptive phenomenological approach will be adopted to gain an accurate and unbiased description of the lived experience. An estimated ten pediatric intensive care nurses in Hong Kong will be invited to undergo individual, in-depth, semi-structured interviews. Hence to obtain pediatric intensive care nurses' detailed information so as to reveal the essence of Nurse-Caregiver Relationship in PICU.

Data will be analyzed using Colaizzi's seven-step strategy as it aligns with the study aim and is able to obtain the meaning of experience. This qualitative study may disclose the nurse-caregiver relationship and the complex nursing relationship role in the context of PICU in Hong Kong and allow clinical reasoning to improve FCC via understanding pediatric intensive care nurses' experience.
RFC1 disease, caused by biallelic repeat expansion in RFC1, is clinically heterogeneous in terms of age of onset, disease progression and phenotype. We investigated the role of the repeat size in influencing clinical variables in RFC1 disease. We also assessed the presence and role of meiotic and somatic instability of the repeat. In this study, we identified 553 patients carrying biallelic RFC1 expansions and measured the repeat expansion size in 392 cases. Pearson's coefficient was calculated to assess the correlation between the repeat size and age at disease onset. A Cox model with robust cluster standard errors was adopted to describe the effect of repeat size on age at disease onset, on age at onset of each individual symptoms, and on disease progression. A quasi-Poisson regression model was used to analyse the relationship between phenotype and repeat size. We performed multivariate linear regression to assess the association of the repeat size with the degree of cerebellar atrophy. Meiotic stability was assessed by Southern blotting on first-degree relatives of 27 probands. Finally, somatic instability was investigated by optical genome mapping on cerebellar and frontal cortex and unaffected peripheral tissue from four post-mortem cases. A larger repeat size of both smaller and larger allele was associated with an earlier age at neurological onset [smaller allele hazard ratio (HR) = 2.06, P < 0.001; larger allele HR = 1.53, P < 0.001] and with a higher hazard of developing disabling symptoms, such as dysarthria or dysphagia (smaller allele HR = 3.40, P < 0.001; larger allele HR = 1.71, P = 0.002) or loss of independent walking (smaller allele HR = 2.78, P < 0.001; larger allele HR = 1.60; P < 0.001) earlier in disease course. Patients with more complex phenotypes carried larger expansions [smaller allele: complex neuropathy rate ratio (RR) = 1.30, P = 0.003; cerebellar ataxia, neuropathy and vestibular areflexia syndrome (CANVAS) RR = 1.34, P < 0.001; larger allele: complex neuropathy RR = 1.33, P = 0.008; CANVAS RR = 1.31, P = 0.009]. Furthermore, larger repeat expansions in the smaller allele were associated with more pronounced cerebellar vermis atrophy (lobules I-V β = -1.06, P < 0.001; lobules VI-VII β = -0.34, P = 0.005). The repeat did not show significant instability during vertical transmission and across different tissues and brain regions. RFC1 repeat size, particularly of the smaller allele, is one of the determinants of variability in RFC1 disease and represents a key prognostic factor to predict disease onset, phenotype and severity. Assessing the repeat size is warranted as part of the diagnostic test for RFC1 expansion.
The invention discloses a Chinese medicine patch which is used externally and used for treating tonsillitis and pharyngitis and a method for preparing the Chinese medicine patch. The Chinese medicine paster comprises medicine and matrix. The matrix is vaseline and sesame oil. The medicine is mainly made of artificial cowbezoar, menthol, processed pangolin and forsythia. The preparation method is as follows: according to the mass ratio of the raw materials, 3 to 5 parts of borneol, 3 to 5 parts of the artificial cowbezoar, 2 to 4 parts of the menthol, 3 to 5 parts of the processed pangolin or one part of musk and 20 to 30 parts of blackberry lily and the forsythia or 20 to 30 parts of scutellaria and rhubarb are chosen; the borneol, the menthol, the processed pangolin, the artificial cowbezoar and the musk are respectively ground into powder; the blackberry and the forsythia or the scutellaria and the rhubarb are extracted by ethanol to make extract powder; all the obtained powder are evenly mixed; the quality matrix, such as the mixed powder, is added, air-dried to ointment and coated on backing to form the flux-core with the diameter of 3cm; and the flux-core is covered by a protective film and packed by sealing to obtain the Chinese medicine patch. The Chinese medicine patch has effective curative effect on acute/chronic tonsillitis, tonsil hypertrophy, acute/chronic pharyngitis and parotitis, etc.
4564. Zimmermann, A., [Chemische Fabrik auf Akt. vorm. E. Schering]. Feb. 24. Albumose compounds ; amines. - Compounds mainly useful in therapeutics are prepared by the action of albumose on the double compounds of silver salts with organic bases. In examples, ethylenediamine in combination respectively with silver nitrate, carbonate, and phosphate, is combined with albumose in aqueous solution ; and piperazine, in combination with silver nitrate, is also combined with albumose. The silver compounds of the organic bases are prepared by interaction of the silver salt with an aqueous solution of the base, and may be isolated as solids. Silver phosphate is prepared by the action of sodium phosphate on silver nitrate in aqueous solution. According to the Provisional Specification, the solutions of the products possess antiseptic power.
This invention relates to the field of biological medicine preoaration including using the administration by gavage of B mouse trough the abstract of the water of common anemarrhena rhizome to discover the expressiom of specific restraining uncoupling protein 2(UCP2), so to treat the insulin resistance. Use water to decoct common anemarrhena rhizome, condense the decocted common anemarrhena rhizome water by using rotating vaporator, reduce vaportator's pressure and dry the condensed liquid in cold so to gain the condensed crystal abstracts. Use the abstracts to prepare a given thickness water solution. Perfuse the solution into the rat's stomach, it can obviously show that this solution can restrain the UCP2 in the rat's kidney. This invention has clarifie that the extracted liueid of common anemarrhena rhizome can specificly restrain UCP2 in the kidney. It can be developed into medicine that can improve and treat insulin resistance.
Attention-Deficit/Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder that often persist to adulthood. In Malaysia, the Chinese ethnic is having the highest prevalence rate of hyperactivity symptoms. Nevertheless, there are only limited evidence-based treatment options targeting the core symptoms of ADHD, as well as executive functions in adulthood. In addition, conventional psychotherapeutic approaches for adults with ADHD have found to be highly labor-intensive. Emerging adulthood is a distinct developmental stage of 18 - 29 years old, with unique challenges that rarely addressed in mental health system. Recently, mindfulness-based intervention appears to be a promising treatment for adults living with ADHD but it has not been evaluated among Malaysian emerging adults with ADHD. The investigators proposed a two-arm randomized controlled trial, comparing an eight-week online mindfulness-based intervention program with an online introductory psychology program. The outcomes include changes of inattention symptom, changes of hyperactivity-impulsivity symptom, and changes of executive functions from pretest to posttest, 1-month follow-up and 3-month follow-up. To investigators' best knowledge, this randomized controlled trial will be the first to test the efficacious of online mindfulness-based intervention for ADHD among emerging adults. It will provide evidence on the efficacious of online treatment for this often-overlooked population in the mental healthcare system.
Group will undergo usual mobilization per standard ICU care. Conventional physical and respiratory therapy were provided by the ICU physical therapists twice daily, for approximately 30 min, 7 days per week. The protocol included vibrocompression maneuvers; lung hyperinflation by the mechanical ventilator; and tracheal aspiration, when necessary; as well as passive and active-assisted motor exercises for arms and legs, depending on the clinical course of patients.
Polymorphic crystal forms of 3-methylthiophene-2-carboxylic acid (6S,9R,10S,11S,13S,16R,17R)-9-chloro-6-fluoro-11-hydroxy-l7-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-l7-yl ester of formula (I) are disclosed. The crystal forms possess anti-inflammatory activity and have very good stability. Methods for preparing the crystal forms are also described. Particularly disclosed is a compound of formula (I) in a crystal form A that has a melting point, by Differential Scanning Calorimetry, of about 264 deg. C with simultaneous decomposition, at a heating rate of 20 deg. C/min and the diffraction lines (2theta in angular degrees ñ 0.2 deg.) in the X-ray diffraction pattern as defined in the specification. (62) Divided Out of 537868
INTRODUCTION AND OBJECTIVES: Limited data exist on the prognostic usefulness of transthoracic echocardiography preceding MitraClip for chronic primary mitral regurgitation (MR). We evaluated the predictive ability of transthoracic echocardiography in this setting.
METHODS: A total of 410 patients (median age, 83 years, 60.7% males) were included in the study. The primary outcome was the 1-year composite of all-cause mortality or heart failure hospitalization. Secondary endpoints encompassed individual elements of the primary outcome, the persistence of significant functional impairment or above-moderate MR at 1 year, and above-mild MR at 1-month.
RESULTS: The only parameter associated with the risk of the primary outcome was a ventricular end systolic diameter index of ≥2.1 cm/m2, corresponding to the cohort's 4th quartile (HR, 2.44; 95%CI, 1.09-4.68; P=.022). Concurrently, higher left atrial volume index (LAVi) and a mid-diastolic medial-lateral mitral annular diameter (MAD) equal to or above the cohort's median of 32.2mm were linked to a higher probability of death and heart failure hospitalization, respectively. LAVi of ≥ 60mL/m2, above-mild mitral annular calcification, and above-moderate tricuspid regurgitation conferred higher odds of functional class III-IV or above-moderate MR persistence. All variables except LAVi and MAD, as well as indexed mid-diastolic medial-lateral MAD of ≥ 20.2mm/m2 and mitral effective regurgitant orifice area of ≥ 0.40 cm2, were associated with greater-than-mild MR at 1 month.
CONCLUSIONS: Preprocedural increased indexed left heart dimensions, mainly left ventricular end-systolic diameter index, MAD, mitral annular calcification, mitral effective regurgitant orifice area, and tricuspid regurgitation mark a less favorable course post-MitraClip for chronic primary MR.
Low frequency stimulation is an attractive, uninvestigated method for treatment of intractable epilepsy. Preliminary animal and human data suggest safety and remarkable efficacy of Low frequency stimulation (LFS) in epilepsy. In addition, the duty cycle of LFS is very low, implying less electric current injection, with less charge density on the target tissue and electrodes, and longer battery life. The current project is a classic translational, single-blinded, randomized research project, demonstrating a clear path from the laboratory to bedside. If successful, this new therapy will be of great value to patients with medically and surgically intractable Mesial Temporal Lobe Epilepsy (MTLE).

The study is expected to last approximately 5 years, from enrollment of the first patient to completion of the final subject, taking into consideration attrition and otherwise-eligible subjects who will not elect to participate. Once the study is completed, and enrolled participants have completed all required elements of the protocol, a final report will be submitted to the FDA. Participants may also discontinue their participation in the study, if they wish, at any time.
The study will include female individuals aged 19-64 years who applied to Necmettin Erbakan University Meram Medical Faculty General Surgery and Medical Oncology Departments and were diagnosed with breast cancer for the first time and volunteering to participate in the study. Patients with breast cancer will be followed up before surgery, before chemotherapy, and in the sixth and twelfth months after starting chemotherapy.
Essential tremor is a very common form of tremor, occurring in up to 5% of people. It may be inherited. In 90% of patients, the tremor is in the hands; however, it can also be in the head, voice, legs, jaw, and tongue. Essential tremor may be treated by the blood pressure medicine propranolol or the anti-seizure drug primidone. The drawbacks of these drugs are that they tend to lose effectiveness over time, and they may cause side effects. Researchers believe that topiramate, an anti-seizure drug, may be effective in treating essential tremor. In this double blind, placebo-controlled study, patients with essential tremor will start at a low dose of topiramate (25 milligrams) or placebo. The dose will be gradually increased over 12 weeks to a maximum of 400 milligrams daily, taken in two divided doses. Then, each patient will stay on the established dose for the next 12 weeks. During the next phase of the study, the patients will slowly reduce the dose until they stop taking the study drug, after which, patients have the option of taking up to 600 milligrams of topiramate (not placebo) in a 14-week extension of the study. This study was designed to investigate the hypothesis that topiramate will be more effective than placebo in the treatment of essential tremor as measured by the Clinical Rating Scale for Tremor (TRS) and is well tolerated. The TRS is a three part scale that measures tremor location/severity rating, specific motor tasks/function rating, and functional disabilities resulting from tremor. Safety evaluations are assessed throughout the study.

Topiramate or placebo, starting with a dose of 25 mg, then gradually increased over 12 weeks up to 400 mg daily (two 100-mg tablets taken by mouth twice a day) and continued on this dose for 12 weeks in the maintenance phase; up to 600 milligrams of topiramate in the open-label phase.
Lung transplantation (LTx) is the preferred treatment modality for patients with end-stage lung disease. However, despite significant advances in treatment after LTx, comorbidities and medical complications contribute to a major extend to the high morbidity and mortality rate. Chronic kidney disease is common in patients after lung transplantation, and a large proportion of these patients ultimately progress to end-stage renal disease requiring dialysis. Chronic calcineurin inhibitor nephrotoxicity is one of the major risk factors for the development of chronic kidney disease. Mammalian target of rapamycin (mTOR) inhibitors such as everolimus have been increasingly used in combination with calcineurin inhibitors to reduce nephrotoxicity. However, whether a mTOR inhibitor based immunosuppressive regime leads to lower chronic nephrotoxicity remains unknown. The aim of this study is to evaluate whether the switch of the standard immunosuppressive regime after LTx with mycophenolate/tacrolimus/prednisolon to everolimus/tacrolimus/prednisolon is associated with an improved long-term preservation of renal function without increase in rejection rate.
Participants will complete an baseline series of questionnaires, and then meet with the psychologist on their cystic fibrosis care team for 3 weekly meetings to complete the PACE CF program and learn mind-body strategies for pain management. Following completion of the program, they will complete a second assessment that includes another set of questionnaires and a brief qualitative interview to provide feedback about the program.